Follow Us

       


"Like" us on Facebook

Clinical Trials

Disease or Condition
Cancer - Prostate Cancer
Title
Failed all other available Treatment
Description
A Phase 3, randomized, double-blind, controlled trial of cabozantinib (XL184) vs. mitoxantrone plus prednisone in men with previously treated symptomatic castration-resistant prostate cancer

Prostate Cancer - XL184-306 COMET-2/Exelexis
IRB Number
NCT01522443
Inclusion/Notes

For more information, please click here: http://www.clinicaltrials.gov/ct2/show/NCT01522443

Status
Open to Enrollment
Principal Investigator
Gregg Newman, MD
Contact Email
research@ccsb.org
Phone
(805) 898-2117

This is the fat footer - edit page 906 to add content.